News Archive

Lipoxen client win

17 November 2010

Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.

Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.

Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.

http://www.lipoxen.com

back to Latest News

Who We Work With

prev next

Latest News

Walbrook PR - Zamaz plc

20 September 2022

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Zamaz plc (LSE:ZAMZ), the on-line consumer goods business that originates, acquires or licenses, operates and scales small and medium-sized brands with category-winning products on global marketplaces; with a focus on ecologically produced, ethically, and health supportive brands and products. Walbrook is managing the Company’s ongoing communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

https://twitter.com/WalbrookPR

Latest Tweets

Tweets by WalbrookPR